Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
(2023)
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
Introduction: Brodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-3 trials. However, long-term data on brodalumab in a real-life setting are still limited.
Id prodotto:
134782
Handle IRIS:
11562/1100066
ultima modifica:
9 ottobre 2024
Citazione bibliografica:
Gargiulo, Luigi; Ibba, Luciano; Malagoli, Piergiorgio; Amoruso, Fabrizio; Argenziano, Giuseppe; Balato, Anna; Bardazzi, Federico; Burlando, Martina; Giovanni Carrera, Carlo; Damiani, Giovanni; Dapavo, Paolo; Dini, Valentina; Fabbrocini, Gabriella; Franchi, Chiara; Maria Gaiani, Francesca; Girolomoni, Giampiero; Guarneri, Claudio; Lasagni, Claudia; Loconsole, Francesco; Valerio Marzano, Angelo; Megna, Matteo; Sampogna, Francesca; Travaglini, Massimo; Costanzo, Antonio; Narcisi, Alessandra,
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)«FRONTIERS IN MEDICINE»
, 2023
, pp. 1-10